New hope for heart transplant patients: trial tests Kidney-Sparing drug
NCT ID NCT04477629
Summary
This study is testing whether adding the drug belatacept to standard anti-rejection medications is safe for adults who have just received a heart transplant. Researchers want to see if this approach can better protect the new heart while also preserving kidney function, which is a common problem after transplantation. The trial will follow 12 carefully selected patients to monitor for serious side effects and measure how well their kidneys work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Columbia University
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.